Bird Flu > Bird Flu News > AskBio enters patent license agreement with Pfizer for HCV therapy

AskBio enters patent license agreement with Pfizer for HCV therapy
Asklepios BioPharmaceutical, Inc., a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV).